Head-to-head evidence
Panobinostat vs Purinostat Mesylate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: HDAC · full Multiple Myeloma pipeline
Panobinostat
Marketed by Novartis
NCT01023308 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled Phase 3 trial with a large sample (768 patients) and a hard clinical endpoint (progression-free survival), which are all strong design features. However, the posted results show only the median PFS for each arm (12.0 vs 8.8 months) without a stated p-value, hazard ratio, or confidence interval for the treatment comparison, so whether this difference was formally statistically significant cannot be confirmed from the record, capping this at a more limited grade despite the otherwise excellent design.
Purinostat Mesylate
Developed by Chengdu Zenitar Biomedical Technology
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Panobinostat's landscape · Purinostat Mesylate's landscape